Mirzotamab (CAS 2229859-11-2) is an IgG1κ monoclonal antibody targeting CD276/B7-H3 with anti-tumor activity. It conjugates with Clezutoclax, a BCL inhibitor, to form Mirzotamab clezutoclax (ABBV-155), a targeted antibody-drug conjugate (ADC) for research in relapsed/refractory solid tumors, including taxane-based studies.
Key Features:
- Target Specificity: Binds to CD276/B7-H3 on tumor cells.
- Mechanism of Action: Inhibits tumor growth and enhances immune destruction.
- Conjugate: Combines with Clezutoclax for targeted drug delivery.
- Molecular Characteristics: IgG1κ monoclonal antibody.
Applications:
- Cancer Therapy: Investigated for treating solid tumors overexpressing CD276/B7-H3.
- Antibody-Drug Conjugates (ADCs): Used for targeted treatment.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
